ARCHIVES

Phase IIb Trial of Vintafolide-Docetaxel Combination Meets Primary Endpoint of Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

8 Pittsburg Employees Started Coalition That Lasted 8 Days

June 10, 1994

Freireich, Moertel Matched Up Again

February 20, 1981

Protocol Amendments Required For 98 NCI-Sponsored Trials

October 8, 2010

Source Identified for Hepatitis A Contamination of LAK-IL-2 Trials; Six MIs Seen; Rosenberg Updates Intramural Results

October 24, 1986

In Brief: NCI’s Katz Named Director, Arthritis Institute; Hayden Promoted At Bristol-Myers Squibb

July 14, 1995

European regulators plan more rigorous rules for accelerated approval in cancer.

November 11, 2005